speak only as of the date of this release.
We undertake no obligation to publicly release the results of any revisions
to these forward-looking statements that may be made to reflect events or
circumstances that occur after the date of this release or to reflect the
occurrence of unanticipated events.
Investor Relations Contact:
Brian Ritchie - FD
212-850-5683
brian.ritchie@fd.com
Corporate Communications Contact:
John Procter - Gibraltar Associates
202-879-5808
jprocter@gibraltar-llc.com
INSMED INCORPORATED
Consolidated Balance Sheets
(in thousands, except share and per share data)
(unaudited)
March 31, December 31,
2008 2007
Assets
Current assets:
Cash, cash equivalents and short-term
investments $12,030 $16,479
Accounts receivable, net 327 250
Prepaid expenses 110 244
Total current assets 12,467 16,973
Long-term assets:
Restricted cash - long term 2,095 2,095
Investments 108 258
Deferred financing costs, net 142 170
Property and equipment, net - 4
Total long-term assets 2,345 2,527
Total assets $14,812 $19,500
Liabilities and stockholders' equity
Current liabilities:
Accounts payable $804 $904
'/>"/>SOURCE Insmed Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 Related biology technology :1.
Insmed Appoints Dennis M. Lanfear to Board Of Directors2.
Insmed Awarded $2.1 Million by Muscular Dystrophy Association3.
Insmed to Appeal Delisting Notification From Nasdaq4.
Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine5.
Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics6.
Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call7.
Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market8.
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results9.
Insmed Announces Additional Information in Compliance With NASDAQ Rules10.
Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway11.
Insmed to Present at CBI Follow-On Biologics Conference